Prescription drug · ANDA
Levetiracetam NDC 50405-301
Levetiracetam 500 mg/1 · Tablet · Oral · SOHM, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50405-301-01 | 50405030101 | 30 TABLET in 1 BOTTLE (50405-301-01)Marketed from May 27, 2024 | |
| 50405-301-02 | 50405030102 | 120 TABLET in 1 BOTTLE (50405-301-02)Marketed from May 27, 2024 | |
| 50405-301-03 | 50405030103 | 500 TABLET in 1 BOTTLE (50405-301-03)Marketed from May 27, 2024 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Levetiracetam
- Generic name (nonproprietary)
- levetiracetam
- Active ingredients
- Levetiracetam — 500 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- SOHM, Inc.
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 079042
- Marketing start
- Listing expires
- Other FDA classes
- Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
- Identifiers
- Product ID 50405-301_8d5b3de5-1dce-43e9-9858-c0439034f86aSPL ID 8d5b3de5-1dce-43e9-9858-c0439034f86aSPL set ID 0a688786-879b-4e27-a46a-5c86bbfa1292RxCUI 311288, 311289, 311290, 387003UNII 44YRR34555UPC 0350405301029, 0350405302026, 0350405300022
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N450405030101followed by a unit qualifier and the quantityPackage 50405-0301-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Levetiracetam tablets are indicated for the treatment of partial-onset seizures in patients 1 month of age and older (1.1) Levetiracetam tablets are indicated for adjunctive therapy for the treatment of: Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy (1.2) Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy (1.3) 1.1 Partial-Onset Seizures Levetiracetam tablets are indicated for the treatment of partial-onset seizures in patients 1 month of age and older. 1.2 Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy Levetiracetam tablets are indicated as adjunctive therapy for the…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 079042
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Levetiracetam | Levetiracetam 1000 mg/1 | TabletOral | SOHM, Inc. | 50405-303 |
| Levetiracetam | Levetiracetam 250 mg/1 | TabletOral | SOHM, Inc. | 50405-300 |
| Levetiracetam | Levetiracetam 750 mg/1 | TabletOral | SOHM, Inc. | 50405-302 |